Gene expression profiling in breast cancer: Towards individualising patient management

Pathology

Volumn 37, Issue 4, 2005, Pages 271-277

  Murphy, N ^a,b   Millar, E ^c,d   Lee, C S ^b,e  

^a SYDNEY CANCER CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Gene expression profiling; Prognostic predictive markers

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER INVASION; CANCER STAGING; DRUG RESPONSE; FAMILIAL CANCER; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HORMONAL THERAPY; HUMAN; LASER CAPTURE MICRODISSECTION; MAMMOGRAPHY; PATHOGENESIS; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 23944434670     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020500169586     Document Type: Article

References (44)

1. Jemal A, Thomas A, Murray T, et al. Cancer Statistics. CA Cancer J Clin 2002; 52: 23.
2. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6: 229-39.
3. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol 2005; 205: 248-54.
4. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005; 23: 1631-5.
5. th International Conference. January 26-29 2005, St Gallen, Switzerland. Breast 2005; 14 (Suppl 1): S1-56.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomized trials. The Lancet 1998; 351: 1451-67.
7. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005; 51: 494-503.
8. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005; 12: 10-9.
9. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
10. Lewis F, Jackson P, Lane S, et al. Testing for HER2 in breast cancer. Histopathology 2004; 45: 207-17.
11. Zhou BP, Li Y, Hung MC. HER-2/Neu signaling and therapeutic approaches in breast cancer. Breast Dis 2002; 15: 13-24.
12. Rosen JM. Hormone receptor patterning plays a critical role in normal lobuloalveolar development and breast cancer progression. Breast Dis 2003; 18: 3-9.
13. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004; 28: 1076-91.
14. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
15. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
16. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expressing profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
17. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 25: 1999-2009.
18. Goldhirsch A, Wood WC, Gelber RD, et al Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-65.
19. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Int 2001; 93: 979-89.
20. Piccart MJ, Loi S, van't Veer LJ, et al. Multi-centre external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are resuts still outperforming the clinical pathological criteria? Breast Cancer Res Treat 2004; 88: 17 (Abstr 38).
21. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-9.
22. Eifel P, Axelson JA, Costa J, et al. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 2005; 21: 171-8.
23. Jenssen TK, Hovig E. Gene-expression profiling in breast cancer. Lancet 2005; 365: 634-5.
24. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Clin Oncol 2005; 23: 732-40.
25. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-9.
26. Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23: 1169-77.
27. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22: 2284-93.
28. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999; 11: 3396-402.
29. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539-48.
30. Shackney SE, Silverman JF. Molecular evolutionary patterns in breast cancer. Adv Anat Pathol 2003; 10: 278-90.
31. King C, Guo N, Frampton GM, et al. Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays. J Mol Diagn 2005; 7: 57-64.
32. Man YG, Zhang Y, Shen T, et al. cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumour invasion. Breast Cancer Res Treat 2005; 89: 199-208.
33. Schlingemann J, Thuerigen O, Ittrich C, et al. Effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarrays. Nucleic Acids Res 2005; 33: 29.
34. Singh R, Maganti RJ, Jabba SV, et al. Microarray based comparison of three amplification methods for nanogram amounts of total RNA. Am J Physiol Cell Physiol 2004; 288: 1179-89.
35. Adeyinka A, Emberley E, Niu Y, et al. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res 2002; 12: 3788-95.
36. Seth A, Kitching R, Landberg G, et al. Gene expression profiling of ductal carcinomas in situ and invasive breast tumours. Anticancer Res 2003; 23: 2043-51.
37. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 5974-9.
38. Porter DA, Krop IE, Nasser S, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res 2001; 61: 5697-702.
39. Warnberg F, Nordgren H, Bergkvist L, et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001; 85: 869-74.
40. Kononen J, Kallioniemi A, Barlund M, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
41. Kumar B, Venter DJ, Armes JE, et al. Tissue microarrays: a practical guide. Pathology 2004; 37: 295-300.
42. Paik S, Shak S, Tang G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
43. Paik S, Shak S, Tang G, et al. Expression of 21 genes in the recurrence score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP B-20. Breast Cancer Res Treat 2004; 88: 15 (Abstr 24).
44. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 6: 607-16.